KOSPIBiotech & Pharma033270

Korea United Pharm

₩15,680▲ 1.49%2026-11-18 close
Market Cap
₩249.5B
Turnover
₩500M
Volume
30K
Shares out.
15.9M
PER
4.3×
PBR
0.5×
EPS
₩3,564
Dividend Yield
3.96%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩610 per share · Prices as of the 2026-11-18 close

01

Report overview

Improved-Drug Model Faces Earnings Volatility in 2026

The business remains anchored by improved drugs at roughly 60% of sales, but in Q3 2026 operating profit fell 77.4% and the company swung to a controlling-shareholder net loss, highlighting earnings volatility.

  1. 1

    Improved drugs account for about 60% of 2025 sales, with cardiovascular drugs the largest category.

  2. 2

    2025 operating profit was KRW 49.6 billion, down 11.9% from the prior year, and the operating margin fell to 17.2%.

  3. 3

    Q3 2026 net loss attributable to controlling shareholders was KRW 7.02 billion, a swing into loss. The company attributes the weakness partly to an expected recovery charge of about KRW 7.5 billion on a colchicine-free product line and foreign exchange losses.

  4. 4

    In October 2026 the company signed anticancer export contracts worth USD 3.27 million with partners in the Philippines and Vietnam, and its 2026 overseas sales target is USD 30 million.

  5. 5

    The 2026 sales target is KRW 330 billion, and against preliminary January–September sales of KRW 219.1 billion, Q4 would need a sharp increase.

02

Business structure

Korea United Pharm has built its business around improved drugs, which offer easier dosing and market differentiation rather than reliance on generics. Reports indicate improved drugs made up 58% of 2024 sales and about 60% in 2025.

Over the most recent four years, cardiovascular drugs averaged 53.3% of sales and digestive drugs 20.5%.

By product in 2025, the antiplatelet Silostan CR contributed 14.5% of sales, the lipid-lowering Artmacombizel 9.6%, and the functional dyspepsia treatment Gastiin CR 6.1%, so these three products alone account for about 30%.

For 2026 the company is positioning the Silduo sustained-release tablet, a rosuvastatin and cilostazol combination, and Pitaric capsules as new growth drivers, with seven new launches planned during the year.

Overseas, Southeast Asia and international procurement markets are expanding; 2025 overseas sales were reported at about USD 24 million against a 2026 target of USD 30 million. In February 2026 the company said it would expand supply to UN agencies under a 30-product anticancer supply deal with Denmark's Missionpharma.

R&D spending was raised to 11.9% of 2025 sales, according to the CEO. Relative to generic-focused peers, the company's distinguishing feature is that improved drugs enjoy a period of market protection through patent and re-examination systems, which reduces price-competition pressure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩74.4B₩12.5B16.8%
2025Q4₩72.6B₩12.5B17.3%
2026Q1₩73.8B₩11.3B15.2%
2026Q2₩77.2B₩13.3B17.2%
2026Q3₩68.1B₩2.8B4.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩262.5B₩48.2B₩45.3B18.4%13.4%23.7%
2023₩278.9B₩54.9B₩48.3B19.7%12.7%23.8%
2024₩288.7B₩56.3B₩32.5B19.5%8.0%16.7%
2025₩288.8B₩49.6B₩38.3B17.2%8.4%14.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a reported basis, annual sales rose from KRW 262.5 billion in 2022 to KRW 278.9 billion in 2023 (up 6.3%) and KRW 288.7 billion in 2024 (up 3.5%), then were flat at KRW 288.8 billion in 2025.

Sales have grown for three consecutive years from 2023 through 2025, with 2025 the largest year and 2022 the smallest in the 2022–2025 window. Operating profit rose from KRW 48.2 billion in 2022 to KRW 54.9 billion in 2023 (up 14.0%) and KRW 56.3 billion in 2024 (up 2.4%), making 2024 the largest year.

In 2025, however, operating profit fell 11.9% to KRW 49.6 billion, and the operating margin declined from 19.5% in 2024 to 17.2%.

Net profit attributable to controlling shareholders was KRW 45.3 billion in 2022, KRW 48.3 billion in 2023 (up 6.6%), KRW 32.5 billion in 2024 (down 32.8%), and KRW 38.3 billion in 2025 (up 18.0%). In 2024 operating profit edged higher while controlling-shareholder net profit fell sharply, so the two measures diverged.

Operating cash flow was KRW 63.8 billion in 2022, KRW 49.8 billion in 2023, KRW 26.8 billion in 2024 and KRW 51.1 billion in 2025. The debt-to-equity ratio fell from 23.7% in 2022 to 14.3% in 2025, with total equity of KRW 454.6 billion and total liabilities of KRW 64.9 billion at year-end 2025.

Quarterly sales peaked at KRW 77.2 billion in Q2 2026 before falling 11.9% quarter on quarter to KRW 68.1 billion in Q3 2026, down 8.5% year on year. Q3 2026 operating profit was KRW 2.82 billion, down 77.4% from a year earlier, and the company posted a controlling-shareholder net loss of KRW 7.02 billion.

The company attributes this to an expected recovery charge of about KRW 7.5 billion on a colchicine-free product line deducted from sales, plus foreign exchange losses.

Preliminary January–September 2026 sales were KRW 219.1 billion, up 1.4%, while preliminary cumulative operating profit was KRW 27.4 billion, down 26.1% (announced October 30, 2026). Controlling-shareholder net profit for the last four reported quarters (Q4 2025 to Q3 2026) totaled KRW 55.6 billion.

05

Industry analysis

For the domestic pharmaceutical industry, government drug price cuts are the central variable. The government is pushing a revision of the pricing system centered on generics, while improved drugs receive comparatively favorable pricing treatment.

Industry commentary holds that improved drugs require shorter development periods and lower costs than new drugs. According to Korean pharmaceutical association policy materials, improved drugs take four to five years to develop, about one-third of the period for a new drug, at a cost of roughly KRW 3 billion.

Sangsangin Securities analyst Ha Tae-ki said in a report in August 2026 that the impact of drug price cuts should be limited given the 60%-plus improved-drug share. A company official has described improved drugs as generating profit at high unit prices while generics maintain volume at low unit prices.

On profitability, an earlier report (early 2023) cited an industry average operating margin of 7–10% for companies with high product and generic shares; the company's operating margin has ranged between 17% and 20% since 2022. That industry benchmark is dated and should not be applied to today without caution.

Against peers, the company differs from generic-focused drugmakers because its sales rest on its own improved-drug portfolio. In public procurement and export markets, quality systems that meet international agency standards serve as an entry requirement.

In September 2026 the Sejong No. 1 plant passed a Ukrainian regulator's on-site inspection and regained GMP certification, which the company cites as a base for overseas supply.

06

Outlook

The company has set a 2026 sales target of KRW 330 billion and said it aims for 15% growth even after accounting for the drug price cut headwind. The same target sets improved drugs at 60% of sales, with 2026 described as the first year above that level.

The company plans seven new product launches in 2026; the Silduo sustained-release tablet, launched in January 2026, has been given a 2026 sales target of KRW 10 billion. The overseas target for 2026 is USD 30 million, and the medium-term goal is to enter the KRW 500 billion-plus sales range.

In September 2026 the company signed a three-year supply deal worth USD 2.2 million with a Malaysian importer and distributor, with product supply to government-affiliated hospitals scheduled from October 2026.

The USD 3.27 million export contracts with Qualimed in the Philippines and Dai Nam in Vietnam still need to show up as recognized sales.

Against preliminary January–September sales of KRW 219.1 billion, reaching the KRW 330 billion target would require Q4 sales of roughly KRW 110 billion, far above Q3 2026 sales of KRW 68.1 billion.

The company disclosed its 2026 corporate value-enhancement plan on March 17, 2026, stating a goal of expanding shareholder value. Next-generation growth drivers mentioned include in-house development and device integration of inhalers for asthma and COPD.

The commercialization timing of the company's new-drug pipeline has not been specified in the reporting reviewed.

07

Valuation

PER
4.3×
PBR
0.5×
ROE
12.2%
EPS
₩3,564
BPS
₩33,453
Dividend per share
₩610

Valuation is best read by combining earnings trends with the balance sheet. The price-to-book ratio sits below 1x, meaning the share price is under book value attributable to controlling shareholders.

Total equity at year-end 2025 was KRW 454.6 billion and the debt-to-equity ratio was 14.3%, indicating a low leverage burden. Controlling-shareholder net profit over the last four reported quarters totaled KRW 55.6 billion, but that window includes the Q3 2026 net loss, so quarterly earnings swung widely.

When earnings are this volatile, earnings-based multiples are sensitive to the period chosen, so the earnings trajectory matters as much as the level of any multiple. On dividends, the company states that it qualifies as a high-dividend company under Korean tax law and disclosed a 2026 corporate value-enhancement plan.

Over multiple years, earnings stayed profitable from 2022 onward, but 2024 and 2026 showed sharp declines. Comparisons with listed peers need to account for differences in improved-drug share and margin structure.

Because share prices change daily, current multiples and dividend yield should be checked on the live figures shown on the platform.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

High profitability from an improved-drug core

The improved-drug share rose from 58% of 2024 sales to about 60% in 2025. Patent and re-examination protections are cited as reducing price-competition pressure for a period. The operating margin held at 18.4% in 2022, 19.7% in 2023 and 19.5% in 2024.

Expanding export contracts

In September 2026 the company signed a three-year USD 2.2 million supply deal with a Malaysian distributor. In October it signed anticancer export contracts totaling USD 3.27 million with Philippine and Vietnamese partners. The 2026 overseas sales target was set at USD 30 million.

New launches and next-generation pipeline

Seven new products are planned for launch in 2026. Silduo has been given a 2026 sales target of KRW 10 billion. In-house development of asthma and COPD inhalers and P-CAB-class candidates through an affiliate are also under way.

09

Bear factors

Sharp Q3 profit drop and swing to loss

Q3 2026 sales were KRW 68.1 billion, down 8.5% year on year. Operating profit fell 77.4% to KRW 2.82 billion, and the controlling-shareholder net loss was KRW 7.02 billion. The company attributes the weakness to an expected recovery charge of about KRW 7.5 billion and foreign exchange losses.

Drug price cuts and annual earnings swings

2025 operating profit fell 11.9% to KRW 49.6 billion, and the margin declined to 17.2%. The government is pursuing a pricing revision centered on generics. The company's own targets already assume a drug price cut headwind, so pricing pressure could persist.

Q4 burden to reach the target

Preliminary January–September 2026 sales were KRW 219.1 billion, up only 1.4%. Reaching the KRW 330 billion target requires Q4 sales near KRW 110 billion. That compares with KRW 68.1 billion in Q3 2026, so a large step-up is assumed.

10

Risk factors

Policy and pricing risk

The government is pursuing a pricing revision centered on generics. The company says a higher improved-drug share and the buffer role of generics will limit the impact. Sangsangin Securities judged the effect limited in an August 2026 report, but the scope could change if policy direction shifts.

Earnings volatility and one-off items

In Q3 2026 an expected recovery charge and foreign exchange losses affected sales and profit. In 2024 operating profit rose while controlling-shareholder net profit fell 32.8%. Because operating and net profit sometimes diverge, quarterly readings require caution.

Governance transition and pipeline uncertainty

Chairman Kang Deok-young transferred shares to his eldest son, Kang Won-ho, who became the largest shareholder, while the co-CEO structure is expected to remain for now. Chairman Kang's term as an inside director expires in March 2027. The new-drug pipeline sits partly with an affiliate, so the timing of results is uncertain.

11

What to watch next

  1. End of December 2026

    Confirm whether the seven 2026 new products have launched. The early sales of cardiovascular launches such as Silduo against target are the key reference.

  2. January to early February 2027 (typical schedule, not confirmed by company)

    Preliminary Q4 2026 results. Combined with January–September sales of KRW 219.1 billion (preliminary), they indicate whether the KRW 330 billion target is attainable.

  3. End of March 2027

    The 2026 annual report, the next periodic filing, is due. It will show the full-year operating margin, the improved-drug sales share, and how the recovery charge is reflected.

  4. March 2027

    At the annual general meeting, the re-election of Chairman Kang Deok-young as inside director, whose term expires, will be decided. It indicates the pace of the management transition.

  5. Quarterly from Q4 2026

    Check whether the Malaysia, Philippines and Vietnam export contracts convert into deliveries and follow-on orders. Whether contract value shows up in quarterly sales is the key indicator for overseas business.

12

Overall view

Korea United Pharm's business rests on improved drugs at about 60% of sales, with a cardiovascular-centered revenue base. Sales rose for three consecutive years from 2023 through 2025, and the operating margin has moved between 17% and 20%.

However, 2025 operating profit fell 11.9%, and in Q3 2026 operating profit dropped 77.4% and the company swung to a controlling-shareholder net loss. The company attributes this to a temporary setback from an expected recovery charge and foreign exchange losses.

Overseas anticancer export contracts and new launches are growth factors, but reaching the KRW 330 billion sales target requires a sharp Q4 increase. Some analysts view drug price cuts as having limited impact thanks to the improved-drug mix, though outcomes depend on policy direction.

The next checkpoints are the preliminary Q4 2026 results and the full-year operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharmnews.com
  2. dailypharm.com
  3. m.dailypharm.com
  4. dealsite.co.kr
  5. whosaeng.com
  6. m.dailypharm.com
  7. pharm.edaily.co.kr
  8. edaily.co.kr
  9. kpanews.co.kr
  10. businesspost.co.kr
  11. medifonews.com
  12. m.news.nate.com
  13. bosa.co.kr
  14. pharmnews.com
  15. fntimes.com
  16. news.nate.com
  17. mt.co.kr
  18. g-enews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis